














































We appreciate Dr Pareek et al for their
interest in our article.1 In their letter, the au-
thors suggest that heart failure (HF) should be
included in the endpoints of the OXI trial. In
addition, they provide more evidence on the
pleiotropic effects of hydroxychloroquine re-
garding its beneficial effects on lipids and gly-
cemic parameters.
As the authors point out, HF is a frequent
complication after myocardial infarction (MI). In
a cohort study by Gerber et al.2, the cumulative
incidence of HF was 14.7–29.8% at 5 years after
the first MI depending on the angiographic ex-
tent of the coronary artery disease.2 In another
register study, HF developed in 12.6% of the pa-
tients after being discharged from their first MI
during a median follow-up time of 3.2 years.3
As Pareek et al point out, hydroxychloroquine
might induce mild bradycardia and thus it might
be beneficial in patients with HF. However, no
clinical evidence supports this theory. On the
contrary, case reports have shown that
hydroxychloroquine has cardiotoxic effects
that might cause cardiomyopathy and HF in
rare cases after prolonged use.4,5 Thus, it would
be worth considering HF as an endpoint be-
cause at the moment we do not know if the net
effect of hydroxychloroquine treatment would
be positive or negative in terms of the develop-
ment of HF.
As the study protocol of the OXI trial does
not include echocardiographic evaluations, we
will consider performing it to the participants at
baseline and during the control visits. Possible
clinical signs of HF will also be assessed regularly.
Measuring the heart rate for the evaluation of
bradycardia effect of hydroxychloroquine is
integrated in the study protocol, as electrocar-
diographic monitoring of each patient will take
place at every visit.
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